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To compare the eﬃciency of novel mitogenic agents and traditional mitosis inductors, 18 patients with splenic marginal zone
lymphoma (SMZL) were studied. Three cultures using oligodeoxynucleotide (ODN) plus interleukin-2 (IL-2), or TPA, or LPS
were setup in each patient. Seventeen/18 cases with ODN + IL2 had moderate/good proliferation (94,4%) as compared with
10/18 cases with TPA and LPS (55%) (P = .015); 14/18 (77,7%) cases with ODN + IL2 had suﬃcient good quality of banding as
compared with 8/18 cases (44,4%) with TPA and LPS.The karyotype could be deﬁned from ODN+IL2-stimulated cultures in all
18patients,14ofwhom(77,7%)hadacytogenetic aberration,whereasclonalaberrationscouldbe documented in9andin3cases
by stimulation with LPS and TPA, respectively. Recurrent chromosome aberrations in our series were represented by aberrations
of chromosome 14q in 5 patients, by trisomy 12 and 7q deletion in 4 cases each, and by abnormalities involving 11q and 13q in
two cases each. These ﬁndings show that stimulation with ODN + IL2 oﬀers more mitotic ﬁgures of better quality and results in
an increased rate of clonal aberrations in SMZL, making this method ideal for prospective studies aiming at the deﬁnition of the
prognostic impact of cytogenetic aberrations in this disorder.
1.Introduction
Splenic marginal zone lymphoma (SMZL) is an indolent
disease,representing <2%ofthelymphoidneoplasms, which
was recognized as separate clinicopathological entity in
the World Health Organization 2008 (WHO) classiﬁcation
[1]. Studies using conventional cytogenetic analysis and
molecular cytogenetic techniques disclosed a number of
recurrent chromosome and genetic lesions in this disorder
[2]. Due to low spontaneous mitotic activity, stimulation
using 12-O-tetradecanoylphorbol 12-myristate 13-acetate
(TPA), or a combination of TPA and lipopolysaccharide
(LPS) in parallel cultures, was employed in previous studies
[3–8] revealing abnormal karyotypes in 43–72% of the
cases [5, 9]. Indeed, the combination of data derived from
conventional cytogenetic analysis, along with data derived
from the application of ﬂuorescence in situ hybridization
(FISH) and comparative genomic hybridization (CGH) [10,
11], allowed for the deﬁnition of a cytogenetic proﬁle of
SMZL.Deletionofthelongarmofchromosome7isregarded
as the most characteristic anomaly of SMZL [12]; other
recurrent aberrations are represented by total/partial trisomy
3q in 20–40% of the cases and by 14q32/IgH translocations,
+12, 17p/TP53 deletion, 6q−, +12, and +18 in 5–10% of
the cases, as documented in a recent large multicentre study
using the traditional TPA mitogen stimulation [13].2 Journal of Biomedicine and Biotechnology
Because conventional karyotype analysis is the only
method allowing for the visualization in a single experiment
of any type of chromosomal defect, including gains, losses,
and balanced translocations, attention was recently devoted
to the development of eﬃcient mitogenic stimulation. In
chronic lymphocytic leukemia (CLL), the introduction of
stimulation by CpG oligodeoxynucleotide (ODN-DSP30)
combined with IL2 allowed for the identiﬁcation of more
cases with clonal aberrations than in previous analyses using
other mitogens and showed that a fraction of cases with
apparently normal FISH results may carry chromosome
lesions in regions not covered by conventional probe panels
[14, 15]. Because the identiﬁcation of an optimal mitogen
stimulation can be expected to reduce the rate of nor-
mal results in low-grade lymphoproliferative disorder, we
designed this study which aimed at analyzing the impact of
the innovative combination of immunostimulatory ODN +
IL2 in cell culture in 18 cases of well-documented SMZL.
2.Design and Methods
2.1. Patients and Samples. Eighteen cases of SMZL seen at
our Institution between 2008 and June 2010 were included
in thepresent analysis (Table 1). Allthepatientswere studied
bycytogeneticanalysis aspart ofdiagnostic workup.Samples
from 13 patients were obtained at disease presentation,
whereas 5 patients were sent for cytogenetic analysis 5–12
months after initial presentation.
Diagnosis was made according to the WHO [1]h i s t o -
pathologic criteria in one patient in whom splenectomy
was performed for diagnostic purposes; in the remaining
17 patients, diagnosis was based on the combination of
presentation features, morphologic and immunologic fea-
tures, and bone marrow ﬁndings [16]. Minimal require-
ments were represented by (a) peripheral and bone marrow
lymphocytosis (i.e., >5 × 109/L B-lymphocytes in the PB
and/or>40%lymphocytesintheBMaspiration orlymphoid
inﬁltrate on biopsy sections), with or without splenomegaly
and minimal adenopathy, (b) morphology consistent with
SMZL (i.e., small-to-medium-sized lymphocytes, with or
without villous lymphocytes and/or plasmacytoid features,
and (c) immunophenotype consistent with chronic B-cell
proliferation with a Matutes score ≤3[ 17].
2.2.ConventionalCytogeneticAnalysis. Conventionalcytoge-
netic analysis was performed on cells obtained from periph-
eral blood (PB) in 14 cases, from BM aspirate in 3 cases,
and from a spleen sample in 1 case (Table 2). Methods for
cytogenetic analysis used in our laboratories were previously
published [18]. Spleensamples were minced with a scalpel to
obtain a single cell suspension. After separation by centrifu-
gation over Ficoll-Hypaque, PB, BM, and splenic cells were
cultured for 72h in 10ml RPMI 1640 (Gibco-Invitrogen)
supplemented with 20% fetal calf serum (FCS-Gibco-
Invitro-gen), 2mmol/L GlutaMAX (Gibco-Invitro-gen),
100U/mL penicillin, and 100µg/mL streptomycin (Gibco-
Invitrogen). Three separate cell cultures were setup in all
patients, using the 3 diﬀerent mitogens: (i) 12-O-tetrade-
canoylphorbol 12-myristate 13-acetate (TPA; 50ng/mL–
Table 1: Clinical features at presentation in 18 cases of SMZL.
Median age, y (range) 74 (56–85)
Sex, male/female 13/5
Splenomegaly yes/no 11/7
Lymphadenopathy (yes/no) 1/14
>40% lymphs in the BM aspirate 11/4
Lymphocytosis ≥5 × 109/L yes/no 11/7
Absolute lymphocyte count (×109/L) 0.68–31.49
(median 6,63)
Villous lymphocytes yes/no 6/9
Hb < 12g/dL yes/no 5/13
(8.6–15.2)
Platelet count ≤100 × 109/L yes/no 4/14
(52–239)
CD5 expression yes/no 5/13
Sigma-Aldrich), (ii) lipopolysaccharide (LPS; 40µg/mL–
Sigma-Aldrich), and (iii) immunostimulatory CpG-olig-
onucleotide DSP30 plus IL2 (2µmol/L GpC-ODN-TCG-
TCGCTGTCTCCGCTTCTTCTTGCC) (TibMolBiol, Berlin,
Germany/IL2 100U/mL Stem Cell Technologies Inc)
according to the method described by Dicker et al. [14].
Whenever possible, an additional 72h unstimulated control
culture was setup (6 cases). All cultures were setup with
a cell concentration of 2 × 106/mL and incubated at
37◦Ci na5 %C O 2 fully humidiﬁed atmosphere under
standard conditions which have remained unchanged at
our laboratories during the study period. Colcemid (Kario
Max Colcemid Solution 0,05µg/mL Gibco, Invitrogen) was
added for four hours before harvest. Harvesting and slide
preparation were performed by the same technician (ET)
throughout the study period using hypotonic treatment (20
minutes incubation in 0,075mol/L potassium chloride);
a classical 3:1 methanol/acetic acid solution was used as
ﬁxative. Slides were prepared using a predetermined volume
(i.e., 20µl) of ﬁxed cell suspension, and metaphases were
G-banded with Wright’s stain [19]. Whenever possible, 20
or more metaphases were analyzed from each culture, and
karyotypes were described according to the International
System for Human Cytogenetics Nomenclature (ISCN 2005)
[20]. Complex karyotype was deﬁned by the presence of 3 or
more cytogenetic aberrations in the same clone. To compare
the eﬃciency of the 3 diﬀerent mitogens, the following
cytogenetic features were assessed in the diﬀerent culture
types by visualization at the microscope of the metaphases
present on one slide.
(a) Proliferation. Basedonthenumberofmitoticﬁgures, the
following score was adopted.
Score 1: failure, d e ﬁ n e db yt h ep r e s e n c eo f0 - 1m i t o t i cﬁ g u r e s .
Score 2: poor proliferation, deﬁned by the presence of 2–10
mitotic ﬁgures.
Score 3: moderate proliferation, d e ﬁ n e db yt h ep r e s e n c eo f1 1 –
19 mitotic ﬁgures.
Score 4: good proliferation, deﬁned by the presence of ≥20
mitotic ﬁgures.Journal of Biomedicine and Biotechnology 3
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(b) Quality of Banding. The number of chromosomal bands
per haploid set of chromosomes was counted referring to the
ideograms of banding patterns present in the guidelines of
ISCN 2005 [20]. The following score was adopted.
Score 1: insuﬃcient quality for karyotyping (<100 visible
chromosome bands).
Score 2: poor quality (<200 visible chromosome bands).
Score 3: suﬃcient quality (200–300 visible chromosome
bands).
Score 4: good quality (>300 visible chromosome bands).
(c) Stimulation Eﬃciency. The number of metaphases with
clonal abnormalities in each culture system was evaluated,
and the karyotypes were divided in three groups:.
Score 1: failure, less than 10 analyzable metaphases.
Score 2: normal, absence of clonal abnormalities.
Score 3: abnormal I, karyotype with clonal chromosomal
abnormalities, that is, the same structural rearrange-
ment or chromosome gain in at least two mitotic
ﬁgures, or chromosome loss in at least three mitoses.
3.Results
3.1. Hematologic and Clinical Features. All 18 patients
had an unequivocal diagnosis of SMZL with PB and/or
BM involvement by a clonal expansion of B-lymphocytes
consistent with a marginal zone phenotype as assessed by
immunophenotyping. The patients had 2,9–34,8 × 109/L
PB lymphocytes at time of sampling for cytogenetic analysis,
and no patient had cytologic and/or histologic features
suggestiveoftransformation intohigh-gradelymphoma.BM
involvement with >40% lymphocytes was detected in 11/15
cases, splenomegaly was present in 11/18 cases. A minority
of patients had anemia or thrombocytopenia. Demographics
andhematologicdatainourpatientsarepresentedinTable 1.
3.2. Outcome of Cytogenetic Investigations. The karyotype
could be deﬁned in all 18 cases. No analyzable mitoses were
obtained from 72h unstimulated parallel culture in 6 cases.
The outcome of cytogenetic investigations using diﬀerent
m i t o g e n si ss h o w ni nF i g u r e s1–5.
3.3. Proliferation. Proliferation with at least 1 mitogen
was assessable in all 18 cases. The number of cases with
failure, low, moderate, and good proliferation is shown in
Figure 1. More cases with score 3-4 were seen in ODN+IL2-
stimulatedcultures(17cases=94,4%)ascomparedwithTPA
and LPS (10 cases each; 55,5%) (P = .015).
Seven/18 patients (38,8%) with TPA and 4/18 patients
(22,2%) with LPS had score 1 (failure), whereas no failure
was observed in ODN+IL2-stimulated culture.
3.4. Quality of Banding. The quality of banding expressed as
number of bands in mitotic ﬁgures from the diﬀerent cell
cultures is shown in Figure 2. A good quality of banding
0
2
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12
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P
a
t
i
e
n
t
s
TPA LPS ODN + IL2
Failure
Poor
Moderate
Good
Figure 1: No. of patients with failure, poor, moderate, and good
proliferation following stimulation by diﬀerent mitogens.
0
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8
10
12
Insuﬃcient
Poor
Suﬃcient
Good
TPA LPS ODN + IL2
Figure 2: Quality of banding: black-coloured column corresponds
to insuﬃcient chromosome quality, grey-coloured column corre-
spondsto poor quality,lightgrey andwhitecorrespond tosuﬃcient
and good quality, respectively, in every stimulation procedure.
(score 4) was observed in 3/18 cases with ODN+IL2 and
in no case with TPA or LPS. Overall, 14/18 cases with
ODN+IL2 had score 3-4 (77,7%) as compared with 8/18
cases (44,4%) with TPA and LPS (P = .067). An example
of the quality of chromosome banding is shown in Figure 3.
3.5. Stimulation Eﬃciency. The karyotypes are described
in Table 2, along with outcome measures (i.e., quality of
banding and proliferation score) using diﬀerent mitogens.
The karyotype could be deﬁned from ODN+IL2-stimulatedJournal of Biomedicine and Biotechnology 5
1
6
13 14 15 16 17 18
Y X 22 21 20 19
7 8 9 10 11 12
23 45
(a)
13 14 15 16 17 18
Y X 22 21 20 19
6 7 8 9 10 11 12
123 45
(b)
13 14 15 16 17 18
Y X 22 21 20 19
6 7 8 9 10 11 12
12 3 4 5
(c)
Figure 3: G-banding karyotypes showing some examples of poor quality (score2—(a), patient 14), suﬃcient quality (score3—(b), patient
4), and good quality (score4—(c), patient 16).
cultures in all 18 patients, 14 of whom (77,7%) had a
cytogenetic aberration.
Clonal aberrations could be documented in 9 cases
(50%) and in 3 cases (16,6%) by stimulation with LPS and
TPA, respectively, whereas in the remaining cases, normal
karyotype or failure was observed with these mitogens as
shown in Figure 4.
Five patients had a complex karyotype (pat. 3, 4, 5, 8,
and 16 in Table 2), with numerical gains and structural
abnormalities. One case was in the near-tetraploid range
(pat. 4).The most frequent abnormalities(seeFigure 5)w e r e
represented by aberrations of chromosome 14q in 5 patients,
3 of whom had a 14q interstitial deletion (nos. 3, 11, and 15).
In patient 8 a t(14; 19)(q32; q13) translocation was detected.
Trisomy 12 and 7q deletion were observed in 4 cases each.
Abnormalities involving 11q and 13q were observed in two
cases each.
4.Discussion
Cytogenetic analysis has an established role in the diagnostic
workup [21] and risk assessment of chronic lymphoprolif-
erative disorders [13, 22, 23]. Because the mitotic index in
these indolent disorders is low, stimulation with LPS and TP
was widely employed[3, 24]. Evidencewas recently provided
that conventional karyotyping may allow for the detection
of aberrations, especially translocations, not detectable by
molecular cytogenetic methods [25]a n dt h a tO D N + I L 2
stimulation may disclose more cytogenetically abnormal
cases than was previously thought in CLL [14, 26]. In
particular, in a CLL Research Consortium study, more clonal
abnormalities were observed after culture of CLL cells with
ODN than with the traditional pokeweed mitogen (PWM)
plus TPA [27]. All clonal abnormalities in PWM+TPA
cultures were observed in ODN cultures, whereas ODN
identiﬁed some clones not found by PWM+TPA. These
results were reproducible in ﬁve diﬀerent laboratories, and
all abnormalities were concordant with FISH.
In this study, we were able to show that improved
mitotic stimulation can be obtained in SMZL, a low-
grade lymphoproliferative disorder, by using ODN+IL2 in
analogy with CLL. Indeed, a signiﬁcantly greater number of
mitotic ﬁgures could be observed in ODN+IL2-stimulated
0
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s
Failure
Normal
Abnormal
TPA LPS ODN + IL2
Figure 4: Stimulation eﬃciency: grey colour column represents
abnormalcells,anddarkandwhitecolourcolumnsrepresentfailure
and normal, respectively, in every stimulation procedure.
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
G
a
i
n
(
3
q
)
D
e
l
(
7
q
)
D
e
l
(
1
1
q
)
A
b
n
(
1
3
q
)
A
b
n
(
1
4
q
)
O
t
h
e
r
a
b
n
.
Single
Plus other abn.
G
a
i
n
1
2
N
u
m
b
e
r
o
f
c
a
s
e
s
Figure 5: Total clonal chromosome abnormalities: distribution of
recurrent abnormalities if they were found as single aberration or
in association with other abnormalities.
cultures, which oﬀered chromosomes of better quality with
more clonal aberrations with respect to TPA/LPS-stimulated
cultures. The karyotype could be deﬁned in 100% of6 Journal of Biomedicine and Biotechnology
ODN+IL2-stimulated cultures, 77,7% of which showed a
clonal abnormality, as compared with 50% karyotypically
abnormal cases obtained by a combination of results from
LPS/TPA-stimulated cultures in the same patients. The
percentage of cytogenetically abnormal cases in LPS/TPA-
stimulated cultures was in line with previous reports [5,
9, 13]. It is worth noting that at the time of sampling for
cytogenetic analysis the majority of our patients were at
an initial stage of the disease with moderate lymphocytosis
and splenomegaly, no lymph node involvement, and absence
of anemia or thrombocytopenia in the majority of them.
Interestingly, the capability to detect abnormal clones was
independentofthedegreeoflymphocytosisand BMinvolve-
ment, since all cases with <5 × 109/L lymphocytes in the PB
and with <40% BM lymphocytes could be shown to have an
abnormal karyotype (Table 2).
Thus, our data demonstrate that ODN+IL2 is the
methodofchoicetoenhancecelldivisionsofgoodqualityfor
karyotypinginSMZL,inkeepingwitharecentanalysisdocu-
menting a 97% rate of aberrant karyotypes in 29 SMZL [28].
The cytogenetic proﬁle in our patients conﬁrms that 7q
deletion, 3q abnormalities, +12, and 14q32 translocations
are frequently encountered in this disease. Interestingly, a
14q22-24 deletion occurred as single abnormality in 2 cases
and as additional aberration in 1, resulting in a 16,6%
incidence for this aberration. Only 3% of the SMZL studies
by Salido and coworkers [13] were found to carry 14q
deletions, which showed a 1,5% overall incidence in a study
of 3054 mature B-cell neoplasms [29]. The majority of cases
with 14q deletion in the latter analysis were represented by
atypical CLL cases having a therapy-demanding disease. Our
3 SMZLs with 14q deletion also had a therapy-demanding
disease, requiring treatment after 1, 8, and 13 months from
cytogenetic analysis.
One case in this study with a t(14;19)(q32;q13) adds to
a previous report of 4/330 cases carrying this translocation
[13]. The 14;19 translocation involving IgH and BCL3 is
a rare aberration usually associated with a heterogeneous
group of B-cell malignancies [30], including an atypical
form of CLL with aggressive clinical features [31]. The
identiﬁcation of this subtle rearrangement may be diﬃcult
when banding quality is suboptimal, and it is possible
that improved resolution obtained in ODN+IL2-stimulated
cultures made the detection of this subtle rearrangement
easier. In line with previous studies [32], our case had a
rapidly progressive disease requiring treatment 3 months
after diagnosis due to rapid lymphocyte doubling time.
In conclusion,we have shown that stimulation of mitosis
with ODN+IL2 oﬀers more mitotic ﬁgures of better quality
and results in an increased rate of clonal aberrations in
SMZL, in analogy with CLL. The proﬁle of chromosome
lesions obtained with this mitogen was in line with previous
data, conﬁrming that cytogenetic ﬁndings may be useful
for the diagnosis of this lymphoid neoplasia. The detection
of subtle rearrangements, such as 14q deletion and 14;19
translocations, might have been facilitated by improved
banding resolution. Although more sensitive molecular
genetic techniques using array CGH technology [33]m a y
be of value for the detection of subtle unbalanced genetic
lesions, this cytogenetic method may be ideal for prospective
studied aiming at the deﬁnition of the prognostic impact of
chromosome aberrations in SMZL.
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